Basal cell carcinoma (BCC) is the most common skin cancer, and the vast majority of cases never advance beyond the earliest stage. The five-year relative survival rate is 100%, meaning people diagnosed with BCC live just as long as the general population on average. Still, BCC does have a formal staging system, and understanding it helps you make sense of a diagnosis, grasp what “high risk” actually means, and know what to expect from treatment.
One important detail upfront: the formal TNM staging system for BCC only applies to cancers on the head and neck (lip, ear, face, scalp, and neck). For BCC on the trunk or limbs, doctors rely on a risk-based classification instead. Both frameworks guide treatment decisions, and this article covers both.
How BCC Is Staged: The TNM System
The staging system used since 2018 evaluates three things: the size and depth of the tumor (T), whether cancer has reached nearby lymph nodes (N), and whether it has spread to distant organs (M). Each factor gets a number, and together they determine an overall stage from 0 through IV.
Tumor Size (T)
- T1: The tumor is 2 cm (about ¾ inch) or smaller.
- T2: The tumor is larger than 2 cm but no bigger than 5 cm.
- T3: The tumor is larger than 5 cm (about 2 inches).
- T4: The tumor has grown into nearby bone or deep structures like the skull base.
Most BCCs are caught at T1. A tumor only reaches T3 or T4 if it has been growing undetected for a long time or if it’s an aggressive subtype.
Lymph Node Involvement (N)
Lymph node spread is rare in BCC, but when it happens, it’s classified by the size and number of affected nodes:
- N1: Cancer in a single lymph node on the same side, 3 cm or smaller.
- N2: Cancer in one node between 3 and 6 cm, or in multiple nodes up to 6 cm, or in nodes on both sides of the body.
- N3: Cancer in any lymph node larger than 6 cm.
Distant Spread (M)
M0 means no distant spread. M1 means the cancer has reached organs like the lungs, liver, or bones. Metastatic BCC is extraordinarily uncommon, occurring in well under 1% of all cases.
Overall Stages at a Glance
Combining the T, N, and M values gives an overall stage:
- Stage 0 (carcinoma in situ): Abnormal cells are present but haven’t grown beyond the outermost layer of skin.
- Stage I: The tumor is 2 cm or smaller with no lymph node or distant spread.
- Stage II: The tumor is larger than 2 cm but hasn’t invaded bone or spread to lymph nodes.
- Stage III: The tumor has invaded bone or other deep structures, or cancer has spread to a nearby lymph node.
- Stage IV: Cancer has spread to distant parts of the body, or there is extensive lymph node involvement.
The overwhelming majority of BCC diagnoses fall into Stage I. Stages III and IV are genuinely rare and usually involve tumors that were neglected for years or grew in difficult-to-monitor areas.
Risk-Based Classification: What Matters More in Practice
Because formal staging only covers the head and neck, and because almost all BCC is caught early, doctors more commonly use a risk-based system to guide treatment. This system, developed by the National Comprehensive Cancer Network, sorts every BCC into low-risk or high-risk categories based on several features that predict whether the cancer is likely to come back after treatment.
Location is the single biggest factor. The central face, nose, lips, eyelids, ears, temples, genitalia, hands, and feet are all considered high-risk zones. These areas have thinner tissue, complex anatomy, and higher recurrence rates. The cheeks, forehead, scalp, neck, and shins fall into a moderate-risk category. The trunk and limbs are generally lowest risk.
Size thresholds shift depending on location. A tumor in a high-risk zone (like the nose) is flagged as high-risk once it reaches just 6 mm, roughly the diameter of a pencil eraser. In moderate-risk areas like the forehead or scalp, the threshold is 10 mm. On the trunk or limbs, tumors can be somewhat larger before they raise the same level of concern.
Border definition also matters. If a doctor can clearly see where the tumor starts and ends, that’s a low-risk feature. Tumors with blurry, ill-defined edges tend to have microscopic extensions that make them harder to fully remove.
Depth plays a role too. A tumor on the forehead that stays within the upper layers of skin (the dermis) and is less than 6 mm deep carries a more favorable profile than one that has pushed into fat or muscle.
Growth Patterns That Affect Risk
Not all basal cell carcinomas grow the same way. The specific subtype, identified under a microscope after biopsy, tells doctors a lot about how the cancer will behave.
Nodular BCC is the most common type. It typically appears as a pearly, dome-shaped bump and tends to grow slowly as a contained mass. It’s generally easier to treat because its borders are more predictable.
Superficial BCC stays in the top layer of skin and often looks like a flat, reddish, scaly patch. It’s the least aggressive subtype and is most common on the trunk. Some superficial BCCs can be treated with topical therapies rather than surgery.
Infiltrating and morpheaform BCC are the subtypes doctors worry about most. Rather than forming a neat lump, these cancers send thin tendrils into surrounding tissue, sometimes well beyond what’s visible on the surface. Morpheaform BCC can look like a flat, waxy scar, making it easy to underestimate. These subtypes have higher recurrence rates and almost always require more aggressive treatment.
Micronodular BCC behaves similarly to infiltrating types, with small clusters of cancer cells scattered through the tissue in a pattern that’s difficult to trace with the naked eye.
How Staging and Risk Level Shape Treatment
For low-risk BCC, standard surgical excision with a margin of healthy tissue around the tumor is usually sufficient. The surgeon removes the cancer along with a buffer zone, and the removed tissue is checked to confirm clean edges.
For high-risk BCC, Mohs micrographic surgery is the recommended approach. During Mohs surgery, tissue is removed in thin layers and examined under a microscope in real time. This allows the surgeon to trace every extension of the cancer while removing as little healthy skin as possible. It’s particularly valuable on the face, where preserving tissue matters for both function and appearance. Mohs is also recommended for any BCC that has come back after previous treatment.
Radiation therapy is sometimes used when surgery isn’t practical, either because of the tumor’s location or a patient’s overall health.
For the rare advanced cases (Stage III or IV), treatment may involve targeted medications that block the signaling pathway driving BCC growth. These drugs can shrink tumors that are too large or too invasive for surgery alone.
What “Advanced” BCC Actually Looks Like
Advanced BCC almost always results from years of a tumor growing unchecked. This can happen when a cancer is on the back of the scalp where it’s hard to see, when someone avoids medical care, or in cases where an aggressive subtype was initially misidentified. The tumor may eventually erode into cartilage, bone, or deep tissue.
Lymph node involvement, when it occurs, is typically discovered because a lump appears near the original cancer site. Distant metastasis to organs is so uncommon that large cancer centers may see only a handful of cases per year.
For most people diagnosed with BCC, the cancer will remain a localized, highly treatable problem. The staging system exists primarily for the small percentage of cases where the cancer has grown large or shown aggressive behavior, giving doctors a shared language to plan treatment and track outcomes.